Hims & Hers Health stock falls over 3% as class action lawsuits and legal costs weigh on sentiment

Traders Union
All News
Stocks
Hims & hers slides 3.2% today

Highlights

Several class action lawsuits allege Hims & Hers Health violated federal securities laws for purchases made between August 4, 2025, and July 29, 2026.
The company reported strong international revenue growth but margin pressure and a net loss due to restructuring and legal expenses.
Shares of Hims & Hers Health slipped 3.2% to $28.45 and are expected to trade in a $25.77 to $31.49 range, with technical signals mixed and buyers still dominating intraday momentum.

Mixed growth outlook as lawsuits offset international expansion gains

Several class action lawsuits were filed against Hims & Hers Health, Inc., alleging violations of federal securities laws for purchasers between August 4, 2025, and July 29, 2026. The company reported strong revenue growth from international expansion, but also noted margin pressure and a net loss for the year-to-date period, reflecting restructuring and legal contingency expenses. Hims & Hers Health completed the rebranding of its $1.15 billion Eucalyptus acquisition, launching the Hers platform in Australia to expand women's telehealth services, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees sustained risk for Hims & Hers Health as mounting lawsuits and ongoing restructuring costs undermine investor trust. He views the stock’s struggle below both the 20-day and 50-day moving averages as a sign that technical sellers remain in firm control. Persistent legal issues and a recent net loss highlight structural weaknesses, despite attempts at international growth. Kharitonov notes that the oversold signals are only reducing, not reversing, downside risk. He warns, "I see further legal and structural headwinds capping upside — any rebound could be short-lived given the negative sentiment and unresolved risks."

Viktoras Karapetjanc, expert at Traders Union, believes fundamental momentum remains robust for Hims & Hers Health after the Eucalyptus acquisition and successful expansion into Australia. He notes ongoing revenue growth and new platform launches reinforce the long-term bullish structure. Karapetjanc sees opportunities for further upside if price can reclaim the $29.05 resistance, predicting that legal noise may create attractive entry points for long-term investors. He states, "With strong macro trends in telehealth and ongoing international expansion, I expect further growth — current volatility offers promising setups for upside continuation."

Jainam Mehta, market strategist, highlights a tactical crossroads for Hims & Hers Health. He observes contrasting momentum indicators that suggest neither buyers nor sellers have full control. Mehta sees a potential breakout scenario above $29.05, but also flags the risk of downside if $27.29 support is breached. He comments, "This divergence between MACD and CCI signals a tactical trading window — nimble traders should watch for a directional move as volatility remains elevated."

Long-term trend holds as short-term signals diverge near key levels

Hims & Hers Health is trading below both its 20-day and 50-day moving averages ($29.28 and $29.35), indicating continued near-term and medium-term selling pressure. The price still holds above the 200-day moving average at $27.29, leaving the long-term trend marginally bullish. The Ichimoku Kijun level at $29.05 acts as immediate resistance, while support is established at the 200-day average. Momentum signals show divergence: the MACD points to strong upside momentum, while ADX is neutral. An RSI reading of 50.44 and Stochastic RSI at 51.27 suggest buy signals in a mid-range zone, but the CCI at -101.19 and BBP at 0.36 reflect oversold conditions with buyers maintaining some intraday momentum. The stock is mid-range in a wide daily band, with volatility at 12.29%.

Earlier, analysts noted that Hims & Hers Health had shifted into a more constructive technical position following its Australian expansion, despite lingering legal challenges. The current analysis highlights renewed downside pressure tied to multiple class action lawsuits, with traders now watching the $29.05 resistance and $27.29 support as pivotal levels for a directional move in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.